Shots:

• Viatris reported that its insulin glargine and insulin aspart products are both on track to be approved by the FDA as interchangeable by July 2021
• The biosimilars are the proposed biosimilars of Sanofi’s Lantus and Novo Nordisk’s Novolog/Novorapid products respectively
• If approved- Viatris’s insulin products would be the first biosimilars to receive the US FDA’s interchangeable designations

  Ref: Viatris | Image: Viatris